Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.

Clementi N, Criscuolo E, Castelli M, Clementi M.

New Microbiol. 2012 Oct;35(4):399-406. Epub 2012 Oct 1. Review.

2.

A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza.

Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R.

Antiviral Res. 2011 Oct;92(1):15-26. doi: 10.1016/j.antiviral.2011.07.013. Epub 2011 Jul 21. Review.

PMID:
21798290
3.

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies.

Ekiert DC, Wilson IA.

Curr Opin Virol. 2012 Apr;2(2):134-41. doi: 10.1016/j.coviro.2012.02.005. Epub 2012 Mar 21. Review.

4.

One step closer to universal influenza epitopes.

Li OT, Poon LL.

Expert Rev Anti Infect Ther. 2009 Aug;7(6):687-90. doi: 10.1586/eri.09.48. Review.

PMID:
19681695
5.

Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.

Clementi N, Criscuolo E, Castelli M, Mancini N, Clementi M, Burioni R.

Viruses. 2012 Nov 14;4(11):3090-108. doi: 10.3390/v4113090. Review.

6.

Trends in development of the influenza vaccine with broader cross-protection.

Stropkovská A, Janulíková J, Varecková E.

Acta Virol. 2010;54(1):7-19. Review.

PMID:
20201609
7.

[Immunity against influenza virus infection].

Takada A.

Nihon Rinsho. 2010 Sep;68(9):1625-30. Review. Japanese.

PMID:
20845738
8.

Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.

Martinez O, Tsibane T, Basler CF.

Int Rev Immunol. 2009;28(1):69-92. doi: 10.1080/08830180802593540. Review.

PMID:
19241254
9.

Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.

Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT.

Vaccine. 2016 Oct 26;34(45):5442-5448. doi: 10.1016/j.vaccine.2016.08.057. Epub 2016 Sep 9. Review.

10.

Tackling influenza with broadly neutralizing antibodies.

Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A.

Curr Opin Virol. 2017 Jun;24:60-69. doi: 10.1016/j.coviro.2017.03.002. Epub 2017 May 18. Review.

PMID:
28527859
11.

Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR.

Vaccine. 2013 Mar 15;31(12):1553-9. doi: 10.1016/j.vaccine.2013.01.025. Epub 2013 Jan 29. Review.

12.

Broadly neutralizing antiviral antibodies.

Corti D, Lanzavecchia A.

Annu Rev Immunol. 2013;31:705-42. doi: 10.1146/annurev-immunol-032712-095916. Epub 2013 Jan 16. Review.

PMID:
23330954
13.

Influenza prevention and treatment by passive immunization.

Kalenik B, Sawicka R, Góra-Sochacka A, Sirko A.

Acta Biochim Pol. 2014;61(3):573-87. Epub 2014 Sep 12. Review.

14.

Monoclonal Antibodies against Zika Virus: Therapeutics and Their Implications for Vaccine Design.

Wang Q, Yan J, Gao GF.

J Virol. 2017 Sep 27;91(20). pii: e01049-17. doi: 10.1128/JVI.01049-17. Print 2017 Oct 15. Review.

15.

Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?

Hefferon KL.

Immunotherapy. 2014;6(1):51-7. doi: 10.2217/imt.13.150. Review.

PMID:
24341884
16.

Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.

Sautto G, Mancini N, Gorini G, Clementi M, Burioni R.

Biomed Res Int. 2013;2013:838491. doi: 10.1155/2013/838491. Epub 2013 Aug 22. Review.

17.

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Pelegrin M, Naranjo-Gomez M, Piechaczyk M.

Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005. Review.

PMID:
26433697
18.

Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Clementi N, Mancini N, Solforosi L, Castelli M, Clementi M, Burioni R.

Int J Mol Sci. 2012;13(7):8273-92. doi: 10.3390/ijms13078273. Epub 2012 Jul 4. Review.

19.

Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers.

Herr DR.

Int Rev Cell Mol Biol. 2012;297:45-81. doi: 10.1016/B978-0-12-394308-8.00002-9. Review.

PMID:
22608557
20.

Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Alvarenga LM, Zahid M, di Tommaso A, Juste MO, Aubrey N, Billiald P, Muzard J.

Toxins (Basel). 2014 Aug 21;6(8):2541-67. doi: 10.3390/toxins6082541. Review.

Supplemental Content

Support Center